Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant

Chiu, May; Hague, Samuel; Elinder-Camburn, Anna; Merriman, Eileen; Chan, Henry

doi:10.1016/j.clml.2022.06.010

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[29] Chiu et al retrospectively analyzed transplant-ineligible patients treated with a gemcitabin-based regimen and showed ORR was 33%, EFS was 4.0 months, and OS was 18 months. [30] In our study, after 2 cycles, ORR was 71,4%, after 6 cycles, CR was 38.8%. On the other hand, the results for OS and PFS were positive.…”

Section: Toxicitysupporting

confidence: 50%

Gemcitabine, Dexamethasone, Cisplatin with Rituximab in Treatment Transplant- Ineligible Relapsed Non-Hodgkin B-cell Lymphoma Patients

Nguyen¹,

Nguyen²,

Vu³

2022

Clin Cancer Investig J

View full text Add to dashboard Cite

We conducted this study to find out the effectiveness of treatment as well as some prognostic factors when using R-GDP (Rituximab-Gemcitabine, Dexamethasone, and Cisplatin) regimen to treat transplant-ineligible relapsed non-Hodgkin B-cell lymphoma patients. 49 patients diagnosed with relapsed non-Hodgkin B-cell lymphoma treated with R-GDP (Rituximab-Gemcitabine, Dexamethasone, and Cisplatin) regimen were retrospectively analyzed. Patients who subsequently underwent autologous stem cell transplantation were excluded. After 2 cycles, ORR was 71.4%: CR: 12 patients (24.5%), PR: 23 patients (46.9%). 14 patients (28.6%) who did not achieve at least PR would be treated with another regimen. After 6 cycles, CR was 38.8% (19 patients). Median OS and PFS were 36 and 32 months; respectively. The 5-year rates were 36.4 % and 18.1% for OS and PFS; respectively. No serious side effects were reported. Neutrophilia and thrombocytopenia were grade 3, and grade 2; respectively. Univariate and multivariate analysis showed that LDH ≥237 U/L was an independent adverse prognostic factor for OS (

show abstract

Section: Toxicitysupporting

confidence: 50%